Developing new therapies and diagnostics to fight antimicrobial resistance (AMR) in human and animal health is becoming more important than ever. However, setting up sustainable financing instruments for AMR innovation and bringing novel therapeutics or diagnostics efficiently from bench to bedside are the biggest challenges. Taking place for the third time, the “Novel Antimicrobials and Diagnostics 2019” conference will bring together more than 330 international experts from industry, start-ups, financing, policy and science to discuss these questions. The conference is organised by Berlin-based communication provider BIOCOM with the support of European BEAM Alliance, representing the voice of small and medium-sized enterprises (SMEs) active in the AMR space. “The AMR conference has established as a professional platform for joint discussions and networking for AMR stakeholders from all over the world”, says Sandra Wirsching, responsible for the AMR conference program with BIOCOM.
Whereas many big pharma companies have left the field, hundreds of SMEs are working on new therapeutic and diagnostic solutions to combat multi-resistant pathogens. Different initiatives on the international, European and national level – be it as private action or public-private undertaking – are currently underway to improve the environment for researchers and developers from science and business. As one of the major partners of the conference, BEAM Alliance is urging policy makers for a call to action towards implementing not only push, but also pull incentives. “This includes urgently setting up pilot programs aimed at gaining practical knowledge on utility of the many proposed theoretical incentive models aimed at fixing the current AMR market failure”, says Florence Séjourné, President of the BEAM Alliance and CEO of French Da Volterra.
During the two-day conference, current market access hurdles will be among the major topics discussed by the 75+ international speakers in 12 parallel sessions. “Many stakeholders expect that 2019 will offer a critical turning point in ongoing discussions about push and pull incentives to finance innovation in the AMR space and with our conference program we have tried to bring the most forward-thinking people and new concepts on stage”, says Sandra Wirsching. Representatives from the international AMR accelerator CARB-X, the World Health Organization (WHO), the United Nations Conference on Trade and Development (UNCTAD), the US Food and Drug Administration (FDA), GARDP, DZIF, the European networks JPIAMR and ENABLE, the Global AMR R&D Hub, the new international AMR centre ICARS as well as large pharma and diagnostics corporations, biotech companies and private investors will present updates, new initiatives, and promising approaches to help AMR innovation being developed, financed and brought to the market. Sandra Wirsching, BIOCOM, points out: “For the first time, we implemented an investor partnering which is a great step forward in bringing together AMR-focused therapeutics and diagnostics developers with relevant public and private funders. It turned out to be very successful with more than 200 pre-scheduled one-to-one meetings.”
Furthermore, a total of 10 start-ups have been invited to join the pitch session and receive feedback from an expert financing jury chaired by the Novo REPAIR Impact Fund. The conference also sheds light on early research: Promising academic innovations will be presented during a dedicated track as well as in a poster session showcasing around 50 posters. Based on attendee votings and an expert evaluation, a poster prize winner will be selected and presented by French diagnostics company bioMérieux.
Please note: Journalists receive free entry to the conference.
Press Contact | AMR Conference
D: +49(0) 30-26 49 21-63
M: +49(0) 176 101 439 85